Blocking lymphotoxin-β receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression and leucocyte margination in chronic...

Por STOPFER, P, OBERMEIER, F, DUNGER, N, FALK, W, FARKAS, S, JANOTTA, M, MÖLLER, A, MÄNNEL, D N, HEHLGANS, T
Publicado em 2004

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced...

Por Doebele, R. C., Conkling, P., Traynor, A. M., Otterson, G. A., Zhao, Y., Wind, S., Stopfer, P., Kaiser, R., Camidge, D. R.
Publicado em 2012

Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin

Por Stopfer, P, Giessmann, T, Hohl, K, Sharma, A, Ishiguro, N, Taub, ME, Zimdahl‐Gelling, H, Gansser, D, Wein, M, Ebner, T, Müller, F
Publicado no Clin Pharmacol Ther (2016)

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors

Por Awada, A. H., Dumez, H., Hendlisz, A., Wolter, P., Besse-Hammer, T., Uttenreuther-Fischer, M., Stopfer, P., Fleischer, F., Piccart, M., Schöffski, P.
Publicado em 2012

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off sc...

Por Eskens, F A L M, Mom, C H, Planting, A S T, Gietema, J A, Amelsberg, A, Huisman, H, van Doorn, L, Burger, H, Stopfer, P, Verweij, J, de Vries, E G E
Publicado em 2008